Feasibility of closed-loop insulin delivery in type 2 diabetes: a randomised controlled study
- Dr Kavita Kumareswaran, MBChB FRACP PhD1,
- Dr Hood Thabit, MD MRCPI1,
- Dr Lalantha Leelarathna, MBBS, MRCP, MSc1,
- Karen Caldwell, RN1,
- Daniela Elleri, MD1,
- Janet M Allen, RN1,
- Marianna Nodale, MSc1,
- Dr Malgorzata E Wilinska, PhD1,
- Dr Mark L Evans, MD FRCP1 and
- Dr Roman Hovorka, PhD1⇑
- 1University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Hills Road, Cambridge, CB20QQ, UK
- Corresponding author: Roman Hovorka, E-mail:
Objective Closed-loop insulin delivery offers a promising treatment option, but to date has only been evaluated in type 1 diabetes. Our aim was to evaluate feasibility of fully closed-loop using subcutaneous insulin delivery in insulin-naïve type 2 diabetes.
Research Design and Methods Twelve subjects (7 males, age 57.2y, BMI 30.5 kg/m2) with non-insulin treated type 2 diabetes (HbA1c 8.4% [68 mmol/mol], diabetes duration 7.6y) underwent two 24-hour visits (closed-loop and control) in a randomised crossover design. During closed-loop visits, subjects’ routine diabetes therapy was replaced with model predictive control algorithm-driven subcutaneous insulin pump delivery, based on real-time continuous glucose monitoring. Meals were unannounced and no additional insulin was administered for carbohydrates consumed. During control visits, usual diabetes regimen was continued (metformin 92%, sulfonylureas 58%, DPP-4 inhibitors 33%). On both visits, subjects consumed matched 50-80g carbohydrate meals and optional 15g carbohydrate snacks and remained largely sedentary. Plasma glucose measurements evaluated closed-loop performance.
Results Compared with conventional therapy, 24 hours of closed-loop increased overall median time in target plasma glucose (3.9-8.0 mmol/l) from 24% to 40% (p=0.016), despite sensor under-reading by median 1.2 mmol/l. The benefit of closed-loop was more prominent overnight with greater time in target glucose (median 78% vs. 35%; p=0.041), and less time in hyperglycaemia (22% vs. 65%; p=0.041). There was no hypoglycaemia during either intervention.
Conclusions A closed-loop system without meal announcement using subcutaneous insulin delivery in insulin-naïve type 2 diabetes appears feasible and safe. Improvement in postprandial glucose control may require further optimisation of system performance.
- Received May 1, 2013.
- Accepted August 18, 2013.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.